

## Dafsolimab

|           |   |
|-----------|---|
| Cat. No.: | HY-P99837   |
| CAS No.:  | 2367001-71-4  |
| Target:   | CD3   |
| Pathway:  | Immunology/Inflammation   |
| Storage:  | Please store the product under the recommended conditions in the Certificate of Analysis. |

### BIOLOGICAL ACTIVITY

|                    |   |
|--------------------|---|
| <b>Description</b> | Dafsolimab (SPV-T3a) is an IgG2a murine monoclonal antibody (anti-CD3). Dafsolimab can induce cell death through modulation and activation of the CD3/T cell receptor complex. Dafsolimab can be used for the research of graft-versus-host disease (GVHD) <sup>[1]</sup> .                           |
| <b>In Vitro</b>    | SPV-T3a-dgA (1.8 µg/mL) reduces viable cells 2.0-2.7-fold in the absence of PHA activation. After 48 hours of PHA activation, the maximum lethality of SPV-T3a-DGA increases approximately 3-fold.<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

### REFERENCES

[1]. van Oosterhout YV, et al. A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease. Blood. 2000 Jun 15;95(12):3693-701.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA